Research Progress of Chloroquine and Hydroxychloroquine on the COVID-19 and Their Potential Risks in Clinic Use

In December 2019, a severe outbreak of a novel coronavirus (COVID-19) occurred in the whole world, posing a great threat to people’s health. With the outbreak and development of the epidemic, how to improve the cure rate, find effective drugs against this virus, has been the most urgent problem. Chloroquine (CQ) was verified effective against COVID-19 in vitro. As CQ’s analogue, hydroxychloroquine (HCQ) was also reminded as a potential candidate for treating COVID-19. This review summarizes the latest clinical trials of CQ and HCQ against COVID-19 and its therapeutic regimen in China aiming to share their current usage to the whole world and provide insight into its appropriate future use in the treatment of COVID-19. Through searching the CNKI and Wangfang databases in Chinese language and PubMed, EMBASE, and Ovid databases in English language to identify published reports with the keywords including “coronavirus/COVID, chloroquine, hyroxychloroquine” in alone or combined, we found out the potential preclinical or clinical evidence for using CQ and HCQ against COVID-19. Consequently, we also searched the website of Chinese Clinical Trial Registry (http://www.chictr.org.cn/) till the day on 27th, June, 2020. This review found that there are 23 programs aimed to treat the different phases under COVID-19 pipeline in clinic with CQ and HCQ, totally. The inclusion criteria, exclusion criteria and therapeutic regimen were all shared to consult. Among them, seven have been canceled due to lack of patients or other objective factors. There are two trials have completed, which the potential relationship between usage and adverse reactions was discussed emphatically. Through literature research, we suggested that paid close attention to retinal toxicity and ophthalmologic adverse symptom of CQ and HCQ. And the outcome of HCQ in clinic shows better than CQ especially in protective effect with low dosage.

[1]  T. Brümmendorf,et al.  Favorable COVID‐19 course despite significant comorbidities in a ruxolitinib‐treated patient with primary myelofibrosis , 2020, European journal of haematology.

[2]  Md. Abdul Alim Al-Bari.  Facts and myths: Efficacies of repurposing chloroquine and hydroxychloroquine for the treatment of COVID-19. , 2020, Current drug targets.

[3]  Emily G McDonald,et al.  A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19 , 2020, The New England journal of medicine.

[4]  M. Record,et al.  The endosomal lipid bis(monoacylglycero) phosphate as a potential key player in the mechanism of action of chloroquine against SARS-COV-2 and other enveloped viruses hijacking the endocytic pathway , 2020, Biochimie.

[5]  J. Qu,et al.  Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial , 2020, BMJ.

[6]  Sheng Wang,et al.  The epidemiologic and clinical features of suspected and confirmed cases of imported 2019 novel coronavirus pneumonia in north Shanghai, China , 2020, Annals of translational medicine.

[7]  A. Bhagavathula,et al.  Vaccines and Drug Therapeutics to Lock Down Novel Coronavirus Disease 2019 (COVID-19): A Systematic Review of Clinical Trials , 2020, Cureus.

[8]  Z. Memish,et al.  Therapeutic use of chloroquine and hydroxychloroquine in COVID-19 and other viral infections: A narrative review , 2020, Travel Medicine and Infectious Disease.

[9]  Jens K. Boldsen,et al.  Estimation of SARS-CoV-2 Infection Fatality Rate by Real-time Antibody Screening of Blood Donors , 2020, medRxiv.

[10]  J. Nachega,et al.  Chloroquine and Hydroxychloroquine for the Prevention or Treatment of COVID-19 in Africa: Caution for Inappropriate Off-label Use in Healthcare Settings , 2020, The American journal of tropical medicine and hygiene.

[11]  G. Hripcsak,et al.  Safety of hydroxychloroquine, alone and in combination with azithromycin, in light of rapid wide-spread use for COVID-19: a multinational, network cohort and self-controlled case series study , 2020, medRxiv.

[12]  Zhan Zhang,et al.  Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial , 2020, medRxiv.

[13]  Hongzhou Lu,et al.  [A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19]. , 2020, Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences.

[14]  Science multicenter collaboration group of Department of,et al.  [Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia]. , 2020, Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases.

[15]  L. Meyers,et al.  Risk for Transportation of Coronavirus Disease from Wuhan to Other Cities in China , 2020, Emerging infectious diseases.

[16]  B. Canard,et al.  The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade , 2020, Antiviral Research.

[17]  Wu Zhong,et al.  Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro , 2020, Cell Research.

[18]  E. Holmes,et al.  Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding , 2020, The Lancet.

[19]  H. Cha,et al.  Hydroxychloroquine treatment during pregnancy in lupus patients is associated with lower risk of preeclampsia , 2019, Lupus.

[20]  Rajanish Giri,et al.  Hydroxychloroquine Inhibits Zika Virus NS2B-NS3 Protease , 2018, ACS omega.

[21]  F. Roubille,et al.  Cardiac Complications Attributed to Chloroquine and Hydroxychloroquine: A Systematic Review of the Literature , 2018, Drug Safety.

[22]  Tao Yang,et al.  Hydroxychloroquine Use and Risk of CKD in Patients with Rheumatoid Arthritis. , 2018, Clinical journal of the American Society of Nephrology : CJASN.

[23]  J. Wei,et al.  Hydroxychloroquine may be associated with reduced risk of coronary artery diseases in patients with rheumatoid arthritis: A nationwide population‐based cohort study , 2018, International journal of clinical practice.

[24]  F. Williams,et al.  Steady-state pharmacokinetics of hydroxychloroquine in patients with cutaneous lupus erythematosus , 2018, Lupus.

[25]  Ji‐Won Kim,et al.  Risk of Retinal Toxicity in Longterm Users of Hydroxychloroquine , 2017, The Journal of Rheumatology.

[26]  J. Kabeerdoss,et al.  Chikungunya Infection: a Global Public Health Menace , 2017, Current Allergy and Asthma Reports.

[27]  Hong-Tao Xiao,et al.  Research progress of hydroxychloroquine and autophagy inhibitors on cancer , 2017, Cancer Chemotherapy and Pharmacology.

[28]  P. Garcez,et al.  Chloroquine, an Endocytosis Blocking Agent, Inhibits Zika Virus Infection in Different Cell Models , 2016, Viruses.

[29]  M. Marmor,et al.  Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision). , 2016, Ophthalmology.

[30]  R. Hewson,et al.  Chloroquine inhibited Ebola virus replication in vitro but failed to protect against infection and disease in the in vivo guinea pig model. , 2015, The Journal of general virology.

[31]  Vikas G. Pai,et al.  Efficacy and safety of fixed dose combination of atorvastatin and hydroxychloroquine: a randomized, double-blind comparison with atorvastatin alone among Indian patients with dyslipidemia , 2015, Current medical research and opinion.

[32]  M. Matsuoka,et al.  Hydroxychloroquine-inhibited dengue virus is associated with host defense machinery. , 2015, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[33]  M. Ciccozzi,et al.  Chikungunya virus, epidemiology, clinics and phylogenesis: A review. , 2014, Asian Pacific journal of tropical medicine.

[34]  Paul P. Lee,et al.  Regular examinations for toxic maculopathy in long-term chloroquine or hydroxychloroquine users. , 2014, JAMA ophthalmology.

[35]  Rachel S. G. Sealfon,et al.  Genomic surveillance elucidates Ebola virus origin and transmission during the 2014 outbreak , 2014, Science.

[36]  A. Fawzi,et al.  Progression of hydroxychloroquine toxic effects after drug therapy cessation: new evidence from multimodal imaging. , 2013, JAMA ophthalmology.

[37]  I. D. Manger,et al.  A Systematic Screen of FDA-Approved Drugs for Inhibitors of Biological Threat Agents , 2013, PloS one.

[38]  B. D. da Fonseca,et al.  Chloroquine Inhibits Dengue Virus Type 2 Replication in Vero Cells but Not in C6/36 Cells , 2013, TheScientificWorldJournal.

[39]  Y. Cheung,et al.  Chloroquine for influenza prevention: a randomised, double-blind, placebo controlled trial. , 2011, The Lancet. Infectious diseases.

[40]  Umberto D'Alessandro,et al.  Quinine, an old anti-malarial drug in a modern world: role in the treatment of malaria , 2011, Malaria Journal.

[41]  M. Michaelides,et al.  Retinal toxicity associated with hydroxychloroquine and chloroquine: risk factors, screening, and progression despite cessation of therapy. , 2011, Archives of ophthalmology.

[42]  Mohsin Khan,et al.  Assessment of in vitro prophylactic and therapeutic efficacy of chloroquine against chikungunya virus in vero cells , 2010, Journal of medical virology.

[43]  J. McCullers,et al.  Chloroquine is effective against influenza A virus in vitro but not in vivo , 2007, Influenza and other respiratory viruses.

[44]  I. Donatelli,et al.  Different pH requirements are associated with divergent inhibitory effects of chloroquine on human and avian influenza A viruses , 2007, Virology Journal.

[45]  M. Laakso,et al.  Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial , 2006, The Lancet.

[46]  E. De Clercq,et al.  Design and synthesis of hydroxyferroquine derivatives with antimalarial and antiviral activities. , 2006, Journal of medicinal chemistry.

[47]  Hee‐Choon S. Lee,et al.  The War on Severe Acute Respiratory Syndrome: United States Forces Korea’s Campaign Plan , 2006, Military medicine.

[48]  Roberto Cauda,et al.  New insights into the antiviral effects of chloroquine , 2006, The Lancet Infectious Diseases.

[49]  N. Seidah,et al.  Chloroquine is a potent inhibitor of SARS coronavirus infection and spread , 2005, Virology Journal.

[50]  S. Fowler,et al.  Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the diabetes prevention program: effects of lifestyle intervention and metformin. , 2005, Diabetes.

[51]  V. Samanidou,et al.  Simultaneous determination of quinine and chloroquine anti-malarial agents in pharmaceuticals and biological fluids by HPLC and fluorescence detection. , 2005, Journal of pharmaceutical and biomedical analysis.

[52]  Marc Van Ranst,et al.  In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine , 2004, Biochemical and Biophysical Research Communications.

[53]  Sergio Rutella,et al.  Anti-HIV Effects of Chloroquine: Inhibition of Viral Particle Glycosylation and Synergism With Protease Inhibitors , 2004, Journal of acquired immune deficiency syndromes.

[54]  F. Diaz-Griffero,et al.  Endocytosis Is a Critical Step in Entry of Subgroup B Avian Leukosis Viruses , 2002, Journal of Virology.

[55]  M. Marmor,et al.  Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. , 2002, Ophthalmology.

[56]  M. Laakso,et al.  Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial , 2002, The Lancet.

[57]  R. Chow,et al.  Comparison of hydroxychloroquine with zidovudine in asymptomatic patients infected with human immunodeficiency virus type 1. , 1997, Clinical therapeutics.

[58]  V. Stecher,et al.  Inhibition of HIV-1 replication by hydroxychloroquine: mechanism of action and comparison with zidovudine. , 1996, Clinical therapeutics.

[59]  R. Farinotti,et al.  Clinical Pharmacokinetics and Metabolism of Chloroquine , 1996, Clinical pharmacokinetics.

[60]  P. Winstanley.  Handbook of drugs for tropical parasitic infections (2nd edition). Y. Aden Abdi, L. L. Gustafsson, O. Ericsson & U. Hellgren. London: Taylor & Francis, 1995. x+182pp. Price £18.50. ISBN 07484-0168-7 , 1996 .

[61]  J. Luck.  Periorbital necrobiosis lipoidica. , 1992, The British journal of ophthalmology.

[62]  P. Barriot,et al.  Treatment of severe chloroquine poisoning. , 1988, The New England journal of medicine.

[63]  H. Black,et al.  Left ventricular systolic performance during upright bicycle exercise in patients with essential hypertension. , 1983, The American journal of medicine.

[64]  A. Mackenzie,et al.  Dose refinements in long-term therapy of rheumatoid arthritis with antimalarials. , 1983, The American journal of medicine.

[65]  N. White,et al.  Quinine and Quinidine: A Comparison of EKG Effects During the Treatment of Malaria , 1983, Journal of cardiovascular pharmacology.

[66]  G. R. K. C. B. K. C. M. Ross.  Report on the Treatment of Malaria: Abstract of 2,460 Cases-War Office Investigations. , 1918 .

[67]  Rajanish Giri,et al.  Inhibits Zika Virus NS 2 BNS 3 Protease , 2019 .

[68]  L. Faust,et al.  Handbook Of Drugs For Tropical Parasitic Infections , 2016 .

[69]  M R Prabha Adhikari,et al.  Severe and complicated malaria. , 2002, Indian journal of medical sciences.

[70]  B. Cubitt,et al.  la Cells Mechanism of Borna Disease Virus Entry into , 1997 .

[71]  Severe and complicated malaria. World Health Organization, Division of Control of Tropical Diseases. , 1990, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[72]  E. Ette,et al.  Evaluation of the effect of co-administered paracetamol on the gastro-intestinal absorption and disposition of chloroquine. , 1988, Journal of pharmaceutical and biomedical analysis.

[73]  T. Takahashi.  [Erythematosus]. , 1971, Nihon rinsho. Japanese journal of clinical medicine.